Diabetes News

Endocrinology

sponsor
Become a Member Today!
Register
Email:


Password:

Remember me
Forgot your Password?
Invite Code?
Article ID

Your Article Summary

(Click the title below to leave the MDLinx Network and go to the Journal's Website)

Gul OO et al. – The authors conclude that, in type 2 diabetes mellitus patients, pioglitazone—but not rosiglitazone—significantly raised sRAGE, which may contribute to its antiatherogenic effects.

Related Articles

Role of glucotoxicity and lipotoxicity in the pathophysiology of Type 2 diabetes mellitus and emerging treatment strategies
Diabetic Medicine, 11/25/09    Relevance Score: 90%

Sodium Glucose Cotransporter 2 Inhibitors as a New Treatment for Diabetes Mellitus
Journal of Clinical Endocrinology and Metabolism, 11/10/09    Relevance Score: 90%

Evidence for an association with type 2 diabetes mellitus at the PPARG locus in a South Indian population
Metabolism-Clinical and Experimental, 11/03/09    Relevance Score: 90%

Hepatic fat and inflammation in type 2 diabetes mellitus
Metabolism-Clinical and Experimental, 10/26/09    Relevance Score: 90%

Design of a family-based lifestyle intervention for youth with type 2 diabetes: the TODAY study
International Journal of Obesity, 10/16/09    Relevance Score: 90%

Today in Pharmacology/kinetics...keeping you current

The association between thiazolidinediones and hospitalisation for fracture in type 2 diabetic patients: a Taiwanese population-based nested case-control study
Diabetologia - Clinical and Experimental Diabetes and Metabolism, 12/04/09

Effect of minodronic acid hydrate on hip geometry in Japanese women with postmenopausal osteoporosis
Journal of Bone and Mineral Metabolism, 12/04/09

Myxedema Coma Associated with Combination Aripiprazole and Sertraline Therapy
Annals of Pharmacotherapy, 12/03/09


Sponsor

Article Search

Keyword:

Search:

Published within

Sort By:
Date
Relevance


Sponsor

Send this Summary to a Colleague

Enter email address